Drawing for SBX

USPTO serial 98212299

SBX

Reviewed by CopyMark Law Group

Status 733Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
ALI, STEPHANIE MARIE
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 733: Status 733 means the fourth six-month extension was granted. Only one extension typically remains before you must file a Statement of Use or risk abandonment.

Need help with SBX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*

Plus Government fees of $450

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mona Gupta

Mona Gupta Roche Diagnostics Operations, Inc.9115 Hague RoadIndianapolis, IN 46250United States

Goods and services

ClassDescriptionStatusFirst use
001In vitro diagnostic agents, namely, chemical control solutions for calibrating and monitoring the accuracy and function of instruments and test results, chemical additives, enzymes, reagents, organisms and proteins for use in science, research and industry; reagents for cell separation for scientific or research purposes; labeling reagents for scientific or research purposes; reagents for the processing, separation, isolation, enrichment, depletion, detection, screening, cultivation, analysis and counting of material, in particular of chemicals and biological material, all for scientific or research purposes; reagents featuring magnetic beads for scientific or research purposes; antibody reagents for scientific or research purposes; buffer solutions and reagents for use with laboratory apparatus, namely, separation apparatus and analysis apparatus, for scientific or research purposes; reagents for processing biological material, namely, tissue, bone marrow, cells, blood and components thereof for scientific or research purposes, all of the foregoing excluding reagents used in connection with demineralized bone for purposes other than diagnostic applications; reagents, enzymes, and nucleotides for nucleic acid sequencing for scientific or research purposes; diagnostic tests comprised of reagents and chemical test kits for determination of genetic information for scientific or research purposes; reagents for scientific or medical research use for analyzing cells, proteins, nucleic acids, sequencing dna, genotyping, gene expression profiling and high through-put screening; reagent kits composed primarily of oligonucleotides, enzymes and buffers for nucleic acid detection in the fields of scientific, pharmaceutical and medical research; nucleic acids, enzymes, buffers and chemical reagents for use in genotyping and gene expression test kits for detecting and analyzing nucleic acids for scientific or research purposes; assays and reagents for scientific or medical research use; diagnostic tests and test kits primarily composed of reagents and nucleotides for determination of genetic information for scientific or research purposes; reagents and chemical test kits for scientific and research use in connection with dna sequencing and genetic analysisACTIVE—
005In vitro diagnostic agents, namely, reagents and control solutions for analysis of biological samples, all for medical diagnostic purposes; reagents for medical diagnostic use; medical diagnostic assays and reagents for testing of biological samples; reagent kits consisting of enzymes, oligonucleotides, nucleic acids, natural and modified nucleotides, buffers, labels, and substrates for medical diagnostic purposes; medical diagnostic test kits comprising reagents for testing body fluids to determine fetal chromosomal abnormalities; chemical reagents, preparations and test kits for fetal nucleic acid analysis for medical use; diagnostic kits consisting primarily of reagents for nucleic acid detection and analysis for medical diagnostic purposes; reagents for medical diagnostic use and diagnostic kits comprised of medical diagnostic reagents and assays for use in connection with dna sequencing and genetic analysisACTIVE—
009Scientific equipment, apparatus and instruments, namely, genome sequencer for scientific, pharmaceutical and medical research purposes; scientific instruments for use in scientific research, namely, nucleic acid sequencers, imaging devices and analyzers; laboratory apparatus for sample preparation, amplification, mixing, hybridization, incubation, and washing, namely, arrays, beads, bead sets and flow cells; laboratory equipment, namely, devices for analysis of nucleic acids and for dna sequencing; automated laboratory apparatus and systems, namely, sample loaders and bar code readers; downloadable software used for genotyping and gene expression microarrays for scientific, pharmaceutical and medical research purposes; downloadable software used in analyzing, managing and visualizing dna sequencing data; downloadable software used for preparation of nucleic acids libraries; computer hardware and downloadable software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, for use in the fields of scientific, diagnostic and clinical research and for clinical diagnostic purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 3, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 2, 2026EX4GSOU EXTENSION 4 GRANTED—
Jun 2, 2026EXT4SOU EXTENSION 4 FILED—
Jun 2, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 19, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 18, 2025EX3GSOU EXTENSION 3 GRANTED—
Dec 18, 2025EXT3SOU EXTENSION 3 FILED—
Dec 18, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 13, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 12, 2025EX2GSOU EXTENSION 2 GRANTED—
Jun 12, 2025EXT2SOU EXTENSION 2 FILED—
Jun 12, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 15, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 15, 2024EX1GSOU EXTENSION 1 GRANTED—
Oct 15, 2024EXT1SOU EXTENSION 1 FILED—
Oct 15, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 10, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 10, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 10, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 25, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 30, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 30, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 10, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 23, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 23, 2024DOCKASSIGNED TO EXAMINER—
Oct 14, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 10, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance